Login / Signup

Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.

Young Youn ChoYoung ChangJoon Yeul NamHyeki ChoEun-Ju ChoJeong-Hoon LeeSu Jong YuJung Hwan YoonYun Joon Kim
Published in: Gut and liver (2021)
Patients taking nucleotide analogues had a significantly higher number of renal events than did those taking ETV. Clinicians should be aware of the development of renal toxicity in this patient population. Further long-term studies are warranted.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • hepatitis b virus
  • palliative care
  • peritoneal dialysis
  • prognostic factors
  • case report
  • combination therapy
  • molecular dynamics simulations